全文获取类型
收费全文 | 1088篇 |
免费 | 0篇 |
专业分类
化学工业 | 3篇 |
轻工业 | 2篇 |
石油天然气 | 1篇 |
无线电 | 1篇 |
一般工业技术 | 1篇 |
冶金工业 | 1079篇 |
自动化技术 | 1篇 |
出版年
2020年 | 1篇 |
2002年 | 1篇 |
2000年 | 1篇 |
1999年 | 22篇 |
1998年 | 295篇 |
1997年 | 170篇 |
1996年 | 111篇 |
1995年 | 55篇 |
1994年 | 57篇 |
1993年 | 59篇 |
1992年 | 15篇 |
1991年 | 15篇 |
1990年 | 8篇 |
1989年 | 21篇 |
1988年 | 22篇 |
1987年 | 21篇 |
1986年 | 20篇 |
1985年 | 25篇 |
1983年 | 1篇 |
1982年 | 5篇 |
1981年 | 6篇 |
1980年 | 17篇 |
1978年 | 5篇 |
1977年 | 40篇 |
1976年 | 90篇 |
1975年 | 2篇 |
1968年 | 1篇 |
1955年 | 1篇 |
1954年 | 1篇 |
排序方式: 共有1088条查询结果,搜索用时 15 毫秒
991.
992.
MT Cantorna DA Hullett C Redaelli CR Brandt J Humpal-Winter HW Sollinger HF Deluca 《Canadian Metallurgical Quarterly》1998,66(7):828-831
BACKGROUND: Recently, we have shown that 1,25-dihydroxyvitamin D3 prolongs graft survival in mice and rats when the donor and recipient differ at two or more major histocompatability loci. Among the most serious side effects encountered with the currently available transplantation antirejection drugs are an increased susceptibility to infection and decreased bone mineralization. Our results suggest that 1,25-dihydroxyvitamin D3 prolongs graft survival without these side effects of bone loss and susceptibility to infection. METHODS: We compared the ability of 1,25-dihydroxyvitamin D3-treated, nontreated, or cyclosporine (CsA)-treated mice to resist infection with Candida albicans and herpes simplex virus-1. To determine bone density, femurs were collected from nontreated, 1,25-dihydroxyvitamin D3-treated (50 ng/mouse/day), or CsA-treated (25 mg/kg/day) mice, and bone ash was determined. RESULTS: Here we show that 1,25-dihydroxyvitamin D3 treatment does not increase the susceptibility of the host to fungal or viral infection. Furthermore, CsA causes bone loss, whereas 1,25-dihydroxyvitamin D3 actually increases bone mass. CONCLUSIONS: The use of 1,25-dihydroxyvitamin D3 and its analogs to increase transplant survival will avoid bone loss and opportunistic infection, two important disadvantages of the most widely used transplant antirejection drugs--CsA and the glucocorticoids. 相似文献
993.
994.
R Nau HW Prange M Kinzig A Frank A Dressel P Scholz H Kolenda F S?rgel 《Canadian Metallurgical Quarterly》1996,40(3):763-766
Ceftazidime has proven to be effective for the treatment of bacterial meningitis caused by multiresistant gram-negative bacteria. Since nosocomial central nervous system infections are often accompanied by only a minor dysfunction of the blood-cerebrospinal fluid (CSF) barrier, patients with noninflammatory occlusive hydrocephalus who had undergone external ventriculostomy were studied (n = 8). Serum and CSF were drawn repeatedly after the administration of the first dose of ceftazidime (3 g over 30 min intravenously), and concentrations were determined by high-performance liquid chromatography by using UV detection. The concentrations of ceftazidime in CSF were maximal at 1 to 13 h (median, 5.5 h) after the end of the infusion and ranged from 0.73 to 2.80 mg/liter (median, 1.56 mg/liter). The elimination half-lives were 3.13 to 18.1 h (median, 10.7 h) in CSF compared with 2.02 to 5.24 h (median, 3.74 h) in serum. The ratios of the areas under the concentration-time curves in CSF and serum (AUCCSF/AUCS) ranged from 0.027 to 0.123 (median, 0.054). After the administration of a single dose of 3 g, the maximum concentrations of ceftazidime in CSF were approximately four times higher than those after the administration of 2-g intravenous doses of cefotaxime (median, 0.44 mg/liter) and ceftriaxone (median, 0.43 mg/liter) (R. Nau, H. W. Prange, P. Muth, G. Mahr, S. Menck, H. Kolenda, and F. S?rgel, Antimicrob. Agents Chemother. 37:1518-1524, 1993). The median AUCCSF/AUCS ratio of ceftazidime was slightly below that of cefotaxime (0.12), but it was 1 order of magnitude above the median AUCCSF/AUCS of ceftriaxone (0.007) (Nau et al., Antimicrob. Agents Chemother. 37:1518-1524, 1993). The concentrations of ceftazidime observed in CSF were above the MICs for most Pseudomonas aeruginosa strains. However, they are probably not high enough to be rapidly bactericidal. For this reason, the daily dose should be increased to 12 g in cases of P. aeruginosa infections of the central nervous system when the blood-CSF barrier is minimally impaired. 相似文献
995.
20 human donor corneas were placed in a tissue culture medium (NCTC 135 with an additional content of 5% Actovegin resp. Solcoseryl) at +4 degrees C for 5 and 7 days. After that the temperature reversal effect was measured and the corneal endothelial cells were stained. The living cells were counted every 24 hours until no more cells could be seen. It could be shown, that compared with the MK-Medium 24% more living cells could be counted after 5 and 7 days storage in the medium. Possible causes of this improvement, practical consequences with including antibiotic prophylaxis are discussed. 相似文献
996.
997.
998.
999.
1000.